Mobocertinib is an inhibitor of mutant EGFR and HER2 receptors.1,2 It is selective for the HER2 exon 20 mutants HER2V659E, HER2G660D, HER2G309E, and HER2S310F over wild-type EGFR in Ba/F3 cells.1
1.Chouitar, J., Vincent, S., Brake, R., et al.TAK-788 is a novel and potent tyrosine kinase inhibitor with selective activity against EGFR/HER2AbstractsS811P2(13-32)(2018) 2.Neal, J., Doebele, R., Riely, G., et al.Safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 in NSCLCAbstractsS599P1(13-44)(2018)